$SMMT just fyi, in the US we save the VEGF for 2L Docetaxol/Ramucirumab. I’m guessing any OS benefit in china, if seen, would be due to SoC difference btwn US and china (availability of Cyramza). We tend to avoid the existing VEGF/PD1/chemo option in 1L intentionally
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.